The pricing stage for the company, which will trade on Nasdaq under the symbol GIVN, has been set for September 25. The company is evidently undeterred by Nasdaq's slump below 1,700 points.
During August only five tech companies listed on Nasdaq, compared with about 70 in August 2000. Yet Given's underwriters, Lehman Brothers and Credit Suisse First Boston, subbed by Robertson Stephens and Fidelity, evidently believe the Israeli company can make it.
Given Imaging means to sell 5 million shares at a range of $12 to $14, raising about $65 million according to a company value of $325 million.
As of the end of the second quarter of 2001, the company had no income to report, only an operating loss of $7.7 million for the first half.
Given has developed a diagnostic technology based on its M2A ingestible mini-video-camera. The camera, swallowed in a capsule, records color images of the digestive tract, which it transmits to a recorder the patient wears externally, on a belt. It passes through the system and is excreted naturally.